ENOV:NYSEEnovis Corporation Analysis

Enovis (ENOV) is trading at $22.36, just above its 20‑day SMA of 23.24 and comfortably above the 50‑day SMA of 22.99, but still below the 200‑day SMA of 28.09, indicating a short‑term pullback within a longer‑term downtrend. The RSI of 45.7 signals a neutral momentum environment, while the MACD histogram remains negative (-0.12), suggesting bearish pressure. Volume has been decreasing and the stock sits near the identified support level of $21.40 with resistance around $26.01, a range that has constrained recent moves. Volatility is elevated at roughly 59 % over the past 30 days and beta is high at 1.41, underscoring a sensitivity to market swings.
The fundamentals paint a mixed picture: forward PE of 5.64 is dramatically lower than the industry average of 25.5, and the price‑to‑book ratio of 0.86 suggests the market is pricing the company below its book value. However, the company posted a negative trailing profit margin of -52.7 % and a ROE of -58 %, reflecting recent earnings weakness, while free cash flow remains positive at roughly $104 M. The DCF‑derived fair value of about $3.60 is far below the current price, but analysts’ upside estimate of 102 % and a strong “strong_buy” consensus, driven by a better‑than‑expected adjusted EPS of $0.95 and an upbeat 2026 earnings guide, have propelled the stock up 12.6 % on the news. No dividend is paid, making dividend sustainability a non‑issue.